Fresh from our recent presentation at the “Cabo Meeting” for spine professionals, we bring you a highlight of our ECM technology, which was presented at the meeting; introduce you to our newest team member, Sara D’Imperio; and share some of the recent publications featuring our company in the news. This Issue Features:
1. LATTICE IN THE NEWS:
Fundamental Research Corp. – “Analysts’ Ideas of the Week” features Lattice Biologics: “Lattice Biologics Expanding Network” – Sid Rajeev, B.Tech, MBA, CFA, Head of Research | www.researchfrc.com
On June 29, 2016, Lattice Biologics Ltd. (TSXV: LBL) announced their plans to pursue a private placement to raise up to $0.50 million by issuing units at a unit price of C$0.20. Each unit will consist of a common share and a one-half share purchase warrant (exercise price – C$0.20 for 36 months). The company subsequently announced that the first tranche totaling $0.26 million has been closed. Since our Q2 update report, dated June 6, 2016, the company made a few significant announcements… (see the full article here)
Orthopedics This Week Highlights Lattice Biologics’ Darrell Denslow in a “People in the News” feature: “Darrell Denslow: New National Sales Director at Lattice Biologics”
In the last newsletter we introduced you to our own sales professional extraordinaire and MMA fighter, Darrell ( check out his Q&A here ). Since then, he has been featured in Orthopedics This Week, winner of the MORE Award for Journalistic Excellence in Orthopedics… (see the full article here)
“Congratulations to Lattice Biologics and Darrell Denslow on Darrell’s new position as your National Sales Director, now featured on our website. Wishing Darrell and Lattice Biologics much success!” – Tom Bishow, RRY Publications, LLC / www.ryortho.com
2. INDUSTRY HAPPENINGS: EVENT RECAP: The Spine Technology & Educational Group Organization – 13th Annual “Cabo Meeting” – State of Spine Surgery: A Think Tank – June 30 – July 2
Recently we participated in an exclusive meeting with some of the spine industry’s most respected professionals at the “Cabo Meeting” in Los Cabos, Mexico. The invite-only event shed a bright light on a wide range of topics.
Highlights: The main area of interest for us was the possibility of a second generation BMP-2 (Bone Morphogenic Protein-2, a bone growth factor) product coming to market. ECM (Extracellular Matrix) — one of the main technologies Lattice is focusing on — is packed with BMP-2.
The group displayed some skepticism about the ability to get the product through the FDA in a timely manner considering the side effects associated with the current version of the product. However, allograft tissue was represented as a strong alternative.
Another particularly interesting topic was the growing perception that PEEK (Poly Ethylene Ethylene Ketone, a plastic that is shaped and milled to be used as a spinal implant) spinal implants have questionable long term biocompatibility. Again, allograft tissue was presented as a reasonable alternative.
Lattice Biologics SAB Member, Dr. Richard Guyer, Chairman of the Texas Back Institute, did a fantastic job presenting on our Extracellular Matrix (ECM) technology. (Learn about our ECM Technology here.)
3. MEET THE TEAM: Sara D’Imperio joins Lattice Biologics as new Associate Scientist.
Our newest hire, Sara, hails from Italy, has won multiple equestrian competitions, and earned her Master of Science degree in Biotechnology from the University of California, Irvine. Sara’s research work has focused on 3D cell culture within ECM and she is now bringing her passion for Biomimetics and disease cure research to our scientific team. (Check out her Q&A and get to know Sara!)
Click Subscribe to receive updates.
Follow us on Twitter: @LatticeBio
Melanie Battista, Public Relations, Lattice Biologics Ltd., (TSX-V: LBL) (OTCBB: BLVKF)
16701 N 90th Street, Suite #101, Scottsdale, AZ 85260, 480-563-0800 Office
News@LatticeBiologics.com | www.LatticeBiologics.com